Study #2017-0238
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
Description
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
Information and next steps
Disease:
Mantle-Cell Lymphoma
Study phase:
III
Physician name:
Luhua Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.